Table 2.

The relationship between RNA m6A methylation and Clinical features in breast cancer patient

Types	Component	Regulation	Sources	Clinicopathological features and prognosis	Ref.
Writers	MELLT3	Up-regulation	Normal and Luminal subtypes	MELLT3 associate with worse prognosis.	[23]
		Down	TNBC	MELLT3 associate with better DMFS and OS.	[24, 26]
	WTAP	Down	Breast	Reduced of METTL14 have poor DMFS.	[26]
	METTL14	Up-regulation	Normal, Luminal subtypes	1.Reduced of METTL14 have poor DMFS. 2.METTL14 associate with T staging, without molecular Typing, microvascular invasion, nerve invasion and metastasis.	[26]
	KIAA1429	Down	HER2+ subtype	KIAA1429 associate with intrinsic subclasses, nodal metastasis, and worse OS.	[32]
	CBLL1	Up-regulation	Breast cancer	CBLL1 associate with ER status.	[34]
	ZC3H13	Down	TNBC	Have no association with OS	[87]
Erasers	FTO	Up-regulation	HER2+, Normal, Luminal subtypes, Invasive ductal carcinoma.	1.FTO associate with advanced progression, peritumoral lymphovascular invasion, lymph node metastasis, TNM stage, HER2 status and ER/PR status. 2.FTO associate with shorter DFS/OS/RFS.	[37, 88, 89]
	ALKBH5	Up-regulation	Breast cancer	ALKBH5 have no association with DMFS.	[26]
Readers	YTHDF1 YTHDF2 YTHDF3	Up-regulation	Breast cancer	1.YTHDF1 associate worse OS and RFS 2.YTHDF2 associate brain metastasis 3.YTHDF3 associate with worse OS and RFS	[31, 68, 74]
	FMR1	Up-regulation	Breast cancer	FMR1 associate with high tumor grade (G3) and high Ki67 and easier metastasis to the lungs	[42]
	FXR1	Up-regulation	TNBC	FXR1 associate with worse pCR and poor DFMS and OS.	[46, 58]
	HNRNPA2B1	Up-regulation	Breast cancer	1.Have correlation with endocrine resistance. 2.Associated with worse prognosis	[41]
		Down	Breast Cancer	Associated with better OS.	[90]
	IGF2BP1	Up-regulation	Breast cancer	IGF2BP1 does not affect tumor growth or size.	[55]
	IGF2BP2	Up-regulation	Breast cancer	IGF2BP2 correlate with advanced stage and poor survival.	[55, 91]
	IGF2BP3	Up-regulation	TNBC	1.IGF2BP3 associate with larger size, higher grade, higher clinical stage, necrosis, CK5/6. 2. IGF2BP with worse DFS/OS. 3.IGF2BP3 promote chemoresistance to doxorubicin and mitoxantrone.	[62, 63]
	G3BP1	Up-regulation	Breast cancer	G3BP1 associate with tumor response to the Akt-inhibitor MK-2206.	[82]

Abbreviations: TNBC triple negative breast cancer, RFS relapse free survival, DFS disease free survival, OS overall survival, DMFS distant metastasis free survival